The project aims to develop and clinically test innovative bacteriophage-based medicines — DUOFAG® for treating postoperative wound infections caused by Staphylococcus aureus and Pseudomonas aeruginosa, and TRIOFAG® for respiratory infections caused by Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus. Falling within the Deep Tech field of biotechnological development and production, the project will deliver two functional prototypes — a sterile wound-treatment solution (DUOFAG®) for phase IIa clinical trials and a liquid respiratory solution (TRIOFAG®) for phase I trials — as well as two pilot-scale GMP production units compliant with EMA and SÚKL standards.